|
| Exchange Disseminated Time | Venus Remedies Ltd has informed BSE regarding "Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America"
Announcement :
The Company, has received yet another patent grant from the IMPI (Instituto Mexicano de la Propiedad Industrial) for one of its researched products Sulbactomax, With this grant Venus Remedies has SULBACTOMAX patent in total 42 countries, including Europe, and the patent for this product is valid till 2024.
Venus Remedies will be launching Sulbactomax in the Mexican market by year 2012 and is targeting to capture one per cent of the total USD 176 million anti-infective market in the launch year itself.
The Mexican pharmaceutical market is the worlds ninth largest, leading and the most developed in Latin America. Per-capita spending on pharmaceuticals in Mexico is the highest in Latin America (US$ 110) and is rising at about 6 per cent per year. The Mexican pharmaceuticals market is worth US$ 19.0 billion and is growing at a CAGR of 7.1 per cent.
Mexico, at present, is facing a high prevalence of extended spectrum betalactamases (ESBL) producing and multi-resistant microbes. Sulbactomax effectively kills resistant bacterial strains by breaking bacterial biofilms and has efficacy against penem resistant strains also.
Sulbactomax is the breakthrough in antibiotic therapy with triple mechanism of action.
Sulbactomax, along with a chemical vector as third ingredient, is used for a wide range of indications due to its unique capability of fighting against resistance. It is effective against extended spectrum betalactamases (ESBLs) like lower respiratory tract infections, Urinary Tract Infections, pre and post operative infections." |
|
|